Sanpower Group Closes Acquisition of Dendreon

Comment

Sanpower Group Closes Acquisition of Dendreon

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals LLC (“Dendreon”) today announced the close of a transaction in which Sanpower Group, a private Chinese conglomerate, acquired Dendreon from an affiliate of Valeant Pharmaceuticals International, Inc. for $819.9 million in cash.

Comment

Helpline Frequently Asked Questions

Comment

Helpline Frequently Asked Questions

PCRI's free Helpline connects patients and caregivers with educational advocates and helps them understand their personal case. This article is a top ten frequently asked questions list that our Helpline receives. 

Comment

Marijuana Cures Everything Dude?!

Comment

Marijuana Cures Everything Dude?!

Mark Moyad, MD is a best-selling author and an authority on alternative treatments. In this much-requested article, Dr. Moyad analyzes clinical data and definitively answers common questions about the efficacy of Marijuana on cancer and cancer-related side effects. 

Comment

Prostate Size Matters

Comment

Prostate Size Matters

Prostate size is an additional factor besides Gleason score, PSA, and the percentage of core biopsies involved with cancer, that needs to be considered when going through the treatment selection process.

Comment

Targeted Radiation Administered by Injection

Comment

Targeted Radiation Administered by Injection

Radium-223 Dichloride, otherwise known as Xofigo, is the first alpha-emitting radiopharmaceutical used to treat prostate-cancer-related bone metastasis. The FDA approved Xofigo in May of 2013. The clinical trial that led to the FDA approval was called the ALSYMPCA trial. Eligible patients were randomized in a 2:1 fashion to either receive six monthly intravenous injections of radium-223 or best standard of care, such as antiandrogen hormonal therapy, local external beam radiation, corticosteroids, estramustine, or ketoconazole. The men who received radium-223 had improvement in bone pain and also experienced an increased survival. The patients who were not initially treated with Xofigo were allowed to cross over into the radium-223 arm because of this early noted increased survival. Radium-223 dichloride was also shown to increase the time to symptomatic skeletal events, such as the need for palliative external beam radiation or surgery to treat bone pain and bone fractures. These results led to the FDA fast track approval of this unique radioisotope treatment.

Comment

Prostate Insights Quarterly Newsletter November 2016 | Volume 19, Issue 4

Comment

Prostate Insights Quarterly Newsletter November 2016 | Volume 19, Issue 4

GREETINGS RESEARCHER, and welcome to Prostate Insights! This publication is full of information concerning issues that surround prostate cancer. When dealing with a cancer diagnosis, the main focus is usually the cancer itself. While deciding what treatment to choose, patients may overlook critical issues; issues that most are not prepared to tackle.

Comment